Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2009-11-25

Clinical Trial Update: MK0524A Bioequivalence Study (0524A-059) [Phase 1]

View source ↗

Summary

Phase 1 bioequivalence study of MK0524A (0524A-059) in dyslipidemia has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • MK0524A

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Dyslipidemia | Phase 1 | Status: COMPLETED | Results posted: 2009-11-25